21 articles found
Advocates press Congress to expand Veterans Treatment Courts and restore VA benefits access for incarcerated veterans struggling with service-connected mental health and substance use disorders
New research in Journal of Psychiatric Research reveals individuals with opioid use disorder face 1.88 to 4.17 times greater odds of suicidal thoughts, with moderate cases showing highest attempt rates.
New BMJ research finds semaglutide and similar medications associated with 14% reduced risk of developing substance use disorders and 50% fewer deaths among veterans already in treatment.
Mississippi, Tennessee, Texas, West Virginia, Oklahoma, and Missouri are coordinating clinical trials of ibogaine—a Schedule I psychedelic—for opioid addiction and PTSD despite federal restrictions.
Two competing bills represent fundamentally different approaches to kratom policy—one seeks complete prohibition while the other acknowledges harm reduction uses for addiction recovery and pain management.
University of Cincinnati launches one of nation's largest trials pairing weight-loss drugs with proven addiction medication to improve treatment retention and reduce cravings.
New research from Ohio University finds primary care physicians view opioid use disorder as more treatable than diabetes, yet only 8% have ever prescribed buprenorphine, creating treatment deserts in rural America.
Proposed legislation SB 365 mandates that Connecticut emergency departments offer buprenorphine to patients with opioid use disorder, despite hospital opposition citing costs.
New Nature Mental Health study finds combining low-dose ketamine with mindfulness training improves outcomes for people receiving buprenorphine treatment, opening door to psychedelic-assisted interventions
Somerset County commissioners chose to protect a jail Sublocade program with zero overdose deaths over prevention services as opioid settlement funds run short.
New study finds NET Device reduces opioid and stimulant use for 3 months post-treatment, offering hope for polysubstance addiction amid no approved medications for stimulants
Cychlorphine, an emerging synthetic opioid more potent than fentanyl, has been connected to at least 16 overdose deaths in East Tennessee since October. Federal authorities track 22 samples nationwide as harm reduction officials warn naloxone may require multiple doses.
Mississippi Senate passes HB 314, allocating $5M from opioid settlement funds to join Texas and Arizona in FDA clinical trials of ibogaine for opioid addiction and PTSD treatment.
Weill Cornell research shows state laws eliminating insurance prior authorization for buprenorphine don't significantly improve 180-day retention rates, highlighting need for broader policy interventions.
Civil rights lawsuit alleges Missouri DOC and Centurion Health deny life-saving medication to prisoners with opioid use disorder, despite $7M in settlement funds and rampant drug availability.
Washington University analysis of 600,000+ VA patients finds GLP-1s tied to 50% reduction in drug-related deaths and lower risk across alcohol, opioid, cocaine, and nicotine use disorders.
Missouri's Veterans Mental Health Innovation Act would fund FDA ibogaine clinical trials for opioid use disorder and traumatic brain injury, joining Texas and Arizona in breakthrough therapy research.
State programs like Project Nurture combine prenatal care, substance use treatment, and peer support after Oregon data showed mental health and SUD led pregnancy-related deaths.
In a landmark policy shift, the FDA announced it will approve new drugs based on a single rigorous trial plus confirmatory evidence—a change that could accelerate development of therapies for opioid use disorder, alcohol addiction, and stimulant dependence.
New research from Harvard Medical School shows that just 10 yoga sessions can reduce the most severe phase of opioid withdrawal from nine days to five, offering a promising tool for addiction recovery.
New federal rules allow providers to prescribe six-month supply of buprenorphine via audio-only telehealth for opioid use disorder treatment, eliminating pandemic-era restrictions while implementing safeguards.